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PANCREATITIS HAS A CLINICALspectrum ranging from a mild,self-limiting episode to a severeor fatal event. Case reports and
pharmacoepidemiologic studies have
claimed that statins may cause pancre-
atitis,1-4 although few of these studies
comprehensively considered confound-
ing factors. Very few large randomized
trials of statin therapy have published
data on incident pancreatitis. Recently re-
ported data from the Study of Heart and
Renal Protection (SHARP), a trial com-
paring combination therapy of simva-
statin and ezetimibe with placebo on car-
diovascular events in patients with
chronic kidney disease, demonstrated a
reduction in pancreatitis cases in pa-
tients receiving simvastatin and ezeti-
mibe, suggesting a possible protective as-
sociation.5 In addition, statins reduce bile
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Context Statin therapy has been associated with pancreatitis in observational stud-
ies. Although lipid guidelines recommend fibrate therapy to reduce pancreatitis risk in
persons with hypertriglyceridemia, fibrates may lead to the development of gall-
stones, a risk factor for pancreatitis.
Objective To investigate associations between statin or fibrate therapy and inci-
dent pancreatitis in large randomized trials.
Data Sources Relevant trials were identified in literature searches of MEDLINE,
EMBASE, and Web of Science (January 1, 1994, for statin trials and January 1, 1972,
for fibrate trials, through June 9, 2012). Published pancreatitis data were tabulated
where available (6 trials). Unpublished data were obtained from investigators (22
trials).
Study Selection We included randomized controlled cardiovascular end-point trials
investigating effects of statin therapy or fibrate therapy. Studies with more than 1000
participants followed up for more than 1 year were included.
Data Extraction Trial-specific data described numbers of participants developing
pancreatitis and change in triglyceride levels at 1 year. Trial-specific risk ratios (RRs)
were calculated and combined using random-effects model meta-analysis. Between-
study heterogeneity was assessed using the I2 statistic.
Results In 16 placebo- and standard care–controlled statin trials with 113 800 par-
ticipants conducted over a weighted mean follow-up of 4.1 (SD, 1.5) years, 309 par-
ticipants developed pancreatitis (134 assigned to statin, 175 assigned to control) (RR,
0.77 [95% CI, 0.62-0.97; P=.03; I2=0%]). In 5 dose-comparison statin trials with
39 614 participants conducted over 4.8 (SD, 1.7) years, 156 participants developed
pancreatitis (70 assigned to intensive dose, 86 assigned to moderate dose) (RR, 0.82
[95% CI, 0.59-1.12; P=.21; I2=0%]). Combined results for all 21 statin trials pro-
vided RR 0.79 (95% CI, 0.65-0.95; P=.01; I2=0%). In 7 fibrate trials with 40 162
participants conducted over 5.3 (SD, 0.5) years, 144 participants developed pancre-
atitis (84 assigned to fibrate therapy, 60 assigned to placebo) (RR, 1.39 [95% CI,
1.00-1.95; P=.053; I2=0%]).
Conclusion In a pooled analysis of randomized trial data, use of statin therapy was
associated with a lower risk of pancreatitis in patients with normal or mildly elevated
triglyceride levels.
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cholesterol content,6 which may theo-
retically reduce the risk of developing
gallstones, a risk factor for pancreatitis.
Hypertriglyceridemia has been re-
ported to be the third most common
cause of pancreatitis.7 This has led to ma-
jor guidelines for lipid-modifying thera-
pies, including advice to commence tri-
glyceride-lowering therapy, usually
fibrates, in persons with moderate and
severe hypertriglyceridemia (above 400
to 500 mg/dL [to convert to mmol/L,
multiply by 0.0113]).8,9 However, high-
quality evidence for this approach is lack-
ing, and only observational data ex-
ist.10,11 Indeed, there is concern that
fibrates might increase the risk of pan-
creatitis in individuals with triglyceride
levels lower than those mentioned in
guidelines.12 Fibrates increase the cho-
lesterol concentration in bile and may
increase the risk of gallstones.13,14 How-
ever, few large randomized placebo-
controlled trials of fibrate therapy have
published data on pancreatitis.
Consequently,theassociationsbetween
bothtypesoflipid-modifyingtherapyand
theriskofpancreatitis areuncertain.We
therefore examined the associations be-
tween use of a statin or a fibrate and the
incidence of pancreatitis by conducting
collaborativemeta-analysesofpublished
and unpublished data from the relevant
large randomized clinical trials.
METHODS
Wegathereddata fromlargerandomized
end-point trials primarily designed to
assess the effects of statin therapy (in-
cluding both placebo- and standard
care–controlledtrialsplusintensive-dose/
moderate-dose trials) or fibrate therapy
on cardiovascular events. Inclusion cri-
teria were trials with 1000 or more par-
ticipantsexposedtorandomizedtherapy
withaminimummeanfollow-upof1year,
as inprevious largemeta-analysesofstat-
in trials.15 We excluded trials conducted
inpatientswithpreviousorgantransplan-
tationor those receivinghemodialysis as
well as trials comparing combination
therapy with placebo.
WesearchedMEDLINE,EMBASE,and
WebofSciencedatabasesusingtheterms
statin,HMGCoAreductase inhibitor, and
fibrateand also names of individual stat-
ins (atorvastatin, fluvastatin, lovastatin,
pitavastatin,pravastatin,rosuvastatin,sim-
vastatin) and fibrates (bezafibrate, cipro-
fibrate,clofibrate, fenofibrate,gemfibrozil)
as title words and keywords, limited to
studiesdefinedasrandomizedcontrolled
trials, to identify relevant studies per-
formed in adult patients (initial search
on October 28, 2011; search updated
June 9, 2012) and published from Janu-
ary 1, 1972 (fibrate trials), or January 1,
1994 (statin trials), until June 9, 2012
(FIGURE 1), without language restric-
tions.Reference lists for thestudies iden-
tified in the literature search were
searched for additional studies. The US
Food and Drug Administration website
was also searched for trial reports con-
taining relevant data. Abstracts, manu-
scripts, and reports were reviewed in-
dependently by 2 readers (D.P., P.W.)
inanunblindedfashion.Athirdreviewer
(N.S.) settleddiscrepancies. In thesmall
numberof trials inwhichpublisheddata
regarding incident pancreatitis and
change in triglyceride levels were avail-
able, these data were tabulated. In the
majority of trials in which no relevant
data were available, trial investigators
werecontactedwitharequest toprovide
the required information.
Afterthefullarticleswerereviewedand
datawerereceivedfromcollaborators,21
statin trials5,16-36 (TABLE 1) and 7 fibrate
trials12,37-43 (TABLE2)wereincludedinthe
analyses.Becauseunpublisheddatawere
madeavailableforboththeHelsinkiHeart
Study40 and its smaller ancillary study44
conductedinsimilargroupsofparticipants
randomizedtothesametherapiesoverthe
same follow-uptimes, these resultswere
combined as a single overall study.
Data Sources
Published data for incident pancreatitis
wereavailablefrom2statintrials5,22,36 and
4 fibrate trials.12,37-39,41 Unpublisheddata
werecollectedfrom19statintrials16-21,23-35
and 3 fibrate trials.40,42,43 To examine
whethertherewasarelationshipbetween
theextentoftriglycerideloweringbetween
active and control therapy groups in the
trialsandriskofpancreatitis,wecollected
dataonaveragechangeintriglyceridelev-
elsat1year.APRISMAchecklistwaspro-
vided to the journal at the time of manu-
script submission.45
Quality Assessment
Two authors (D.P., P.W.) used an estab-
lished tool, the Jadad score, to indepen-
dentlyevaluate thequalityofeach trial.46
TheJadadscoreisdesignedtoassesstrials
withregardtomethodofrandomization,
whether the trial is double-blinded, and
whether withdrawals/dropouts are de-
scribed, resulting in a score of up to 5
points.A thirdreviewer(N.S.)wasavail-
able to resolveanydisagreementbycon-
sensus and discussion.
End Points
A patient was considered to have devel-
oped pancreatitis during the trial if this
Figure 1. Literature Search
28 Trials included in meta-analysis
21 Statin
7 Fibrate
39 Full-text articles reviewed for
trial suitability
4082 Records screened
4426 Records identified
4416 From databases
10 From other sources
33 Trials identified as suitable
6 Had published data regarding
incident pancreatitis
27 Unpublished data regarding
incident pancreatitis requested
5 Trials excluded (no data available
or provided)
344 Excluded (duplicates)
6 Excluded
3 Had <1000 participants
1 Follow-up <1 y
1 Surrogate end point
1 Unsuccessful randomization
4043 Excluded a
1650 Surrogate marker end
point, <1000 participants,
or follow-up <1 y
1388 Not randomized (baseline
paper, post hoc analysis,
or review)
590 Nonstatin or fibrate
intervention
415 Other
aMost records excluded for more than 1 reason, with
only the strongest reason recorded.
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was recorded as an adverse event or se-
riousadverseevent.This informationwas
identified using different approaches
across the trials,1 namely text word
searches of adverse event reports, in-
cludingself-reportedhospitalizationdata,
for pancreatitis2; Medical Dictionary for
Regulatory Activities event classifica-
tion3; and International Classification of
Table 1. Baseline Data From 21 Large Statin Trials
Source
No.
Treatment,
Active/Control
Follow-
up, y
Trial Population
(Triglyceride
Inclusion Criteria) Age, y
Triglycerides
Statin Control
Baseline,
Mean (SD),
mg/dL
Difference
at 1 y, %
Placebo- and Standard Care–Controlled Trials
4S,16 1994 2223 2221 Simvastatin (10-40 mg)/
placebo
5.4a Angina or previous MI
(triglycerides222 mg/dL)
134 (45) 18
WOSCOPS,17 1995 3302 3293 Pravastatin (40 mg)/placebo 4.9 Male, hypercholesterolemia,
no history of MI (NR)
55 164 (69) 15
CARE,18 1996 2081 2078 Pravastatin (40 mg)/placebo 5.0a MI in previous 3-20 mo
(triglycerides350 mg/dL)
59 156 (61) 14b
AFCAPS/TexCAPS,19 1998 3304 3301 Lovastatin (20-40 mg)/placebo 5.2 Average cholesterol levels,
no CVD (triglycerides
400 mg/dL)
58 181 (75) 14
LIPID,20 1998 4512 4502 Pravastatin (40 mg)/placebo 6.1 Hospitalization for unstable
angina or previous MI
(triglycerides445 mg/dL)
62a 140a 11b
GISSI Prevenzione,21 2000 2138 2133 Pravastatin (20 mg)/
standard care
2.0a Recent MI (NR) 166 (89) −4
HPS,5,22 2002 10 269 10 267 Simvastatin (40 mg)/placebo 5.4 CVD or diabetes (NR) 65 187 (125) 19
PROSPER,23 2002 2891 2913 Pravastatin (40 mg)/placebo 3.3 Age 70-82 y with CVD or risk
factors (triglycerides
534 mg/dL)
75 138 (62) 17
GREACE,24 2002 800 800 Atorvastatin (to achieve
LDL-C100 mg/dL)/
standard care
3.0 CHD (triglycerides400 mg/dL) 59 181 28
ASCOT-LLA,25 2003 5168 5137 Atorvastatin (10 mg)/placebo 3.3a Hypertension, no CHD
(triglycerides400 mg/dL)
63 147 (80) 23
CARDS,26 2004 1428 1410 Atorvastatin (10 mg)/placebo 3.9a Type 2 diabetes mellitus,
no CVD (triglycerides
603 mg/dL)
62 173 (97) 21
ASPEN,27 2006 1211 1199 Atorvastatin (10 mg)/placebo 4.0 Diabetes mellitus
(triglycerides600 mg/dL)
61 146a 14c
MEGA,28 2006 3866 3966 Pravastatin (10-20 mg)/
no treatment
5.3 Hypercholesterolemia,
no previous CHD
or stroke (NR)
58 148 (83) 6
CORONA,29 2007 2514 2497 Rosuvastatin (10 mg)/placebo 2.7a Systolic heart failure (NR) 73 178 (114) 24d
JUPITER,30 2008 8901 8901 Rosuvastatin (20 mg)/placebo 1.9a No CVD, no diabetes,
hsCRP2.0 mg/L
(triglycerides500 mg/dL)
66a 118 (86-169)a 17
GISSI-HF,31 2008 2285 2289 Rosuvastatin (10 mg)/placebo 3.9a Chronic heart failure (NR) 68 NA NA
Intensive- vs Moderate-Dose Trials
PROVE-IT TIMI 22,32 2004 2099 2063 Pravastatin (40 mg)/
atorvastatin (80 mg)
2.0 Recent hospitalization
for ACS (NR)
58 156a 21a
A to Z,33 2004 2265 2234 Placebo simvastatin (20 mg)/
simvastatin (40-80 mg)
2.0a Recent hospitalization
for ACS (NR)
61a 149 (116-199)a 6
TNT,34 2005 4995 5006 Atorvastatin (80 mg)/
atorvastatin (10 mg)
4.9a Stable CHD (triglycerides
600 mg/dL)
61 151 (71) NA
IDEAL,35 2005 4439 4449 Atorvastatin (80 mg)/
simvastatin (20-40 mg)
4.8a Previous MI (triglycerides
600 mg/dL)
62 149 23
SEARCH,5,36 2010 6031 6033 Simvastatin (80 mg)/
simvastatin (20 mg)
6.7 Previous MI (NR) 64 169 (107) 9
Total 76722 76692 4.3 (1.6)
Abbreviations: ACS, acute coronary syndromes; AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes
Trial–Lipid Lowering Arm; ASPEN, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non–Insulin-Dependent Diabetes Mellitus; A to Z, Aggrastat to Zocor;
CARDS, Collaborative Atorvastatin Diabetes Study; CHD, coronary heart disease; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; CVD, cardiovascular disease;
GISSI-HF, SEARCH Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; GISSI Prevenzione, Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza
cardiaca Prevenzione; GREACE, Greek Atorvastatin and Coronary Heart Disease Evaluation; HPS, Heart Protection Study; hsCRP, high-sensitivity C-reactive protein; IDEAL, Incre-
mental Decrease in Events Through Aggressive Lipid Lowering; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-
density lipoprotein cholesterol; LIPID, Long-term Intervention With Pravastatin in Ischaemic Disease; MEGA, Management of Elevated Cholesterol in the Primary Prevention Group of
Adult Japanese Study Group; MI, myocardial infarction; NA, not available; NR, not reported (no triglycerides inclusion or exclusion criteria specified); PROSPER, Prospective Study of
Pravastatin in the Elderly at Risk; PROVE-IT TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy; TNT, Treating to New Targets; WOSCOPS, West of Scotland Coro-
nary Prevention Study; 4S, Scandinavian Simvastatin Survival Study.
SI conversion factors:To convert triglyceride values mmol/L, multiply by 0.0113; to convert hsCRP values to nmol/L, multiply by 9.524.
aMedian or median (interquartile range).
bAverage difference over 5 years.
cDifference at end of trial.
dDifference at 3 months.
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Diseases classifications (10th revision:
K85, K86.0, K86.1; ninth revision: 577.0,
577.1), according to the preference of
each trial’s investigators. All reports of
pancreatitis were included, regardless of
suggested etiology (information regard-
ing alcohol intake was not available) or
whether the condition was described as
acute, chronic, or neither, based on the
rationale that such additional data may
have been largely absent or variably re-
ported across trials.
Statistical Analysis
Toidentifypotentialassociationsof lipid-
modifying therapies with the risk of de-
veloping pancreatitis, we calculated risk
ratios(RRs)as theratioofcumulative in-
cidence and 95% CIs from the available
data for all trial participants at baseline
and for those who developed pancreati-
tis during trial follow-up. Study-specific
RRs were pooled using a random-effects
modelmeta-analysisas thepreferableap-
proachtomanagepotentialbetween-study
heterogeneity that may have been intro-
ducedby thedifferingmethods for iden-
tifyingparticipantswithincidentpancre-
atitis available in the trials and different
trialpopulations.Fortrialswithnoevents
with randomized or control therapy, a
nominal amount (0.5 cases) was added
to the results for both trial groups.
Statistical heterogeneity across stud-
ies was quantified using both the 2 (or
CochranQ statistic) and I2 statistics, with
P .10 considered statistically nonsig-
nificant. The I2 statistic is derived from
theQ statistic ([Q−df/Q]100) and pro-
vides a measure of the proportion of the
overall variation attributable to between-
study heterogeneity.47
Placebo- and standard care–con-
trolled statin trials plus intensive-dose/
moderate-dose statin trials were ana-
lyzed both separately (with comparison
of analyses by fixed-effect inverse-
variance method) and in a combined
analysis. In sensitivity analyses, only
trials with previously published pancre-
atitis data were examined; fixed-effects
model meta-analyses were also per-
formed. We assessed the potential for
publication bias through formal statis-
tical testing, namely, funnel plots and
Egger tests. To evaluate the potential re-
lationship between the associations of
lipid-modifying agents with incident
pancreatitis and relative reductions in tri-
glyceride levels achieved at 1 year using
statins and fibrates, respectively, ran-
dom-effects meta-regression analyses
were performed.
All P values were 2-sided, and P .05
was considered statistically significant for
the meta-analyses and meta-regression
analyses. Analyses were conducted using
Stata version 10.1 (StataCorp).
RESULTS
Statin Therapy and Pancreatitis
Twenty-onerandomizedclinical trialsof
statin therapy, 2 with published data re-
gardingincidentpancreatitisand19with
unpublished data, provided data on
153414participantsoveraweightedmean
follow-up period of 4.3 (SD, 1.6) years.
Baselineaverage triglyceride levels in the
trials varied from 118 mg/dL to 187 mg/
dL.Trialswereofhighquality,withame-
dian Jadad score of 5 (range, 3-5) and
100% agreement between reviewers.
In 16 placebo- and standard care–
controlled statin trialswith113 800par-
ticipants conducted over 4.1 (SD, 1.5)
years,309participants(0.27%)developed
pancreatitis (134 assigned to statin, 175
assigned to control) (RR, 0.77 [95% CI,
0.62-0.97;P=.03]) (Table 1,FIGURE 2).
Thisrepresentsanumberneededtotreat
Table 2. Baseline Data From Trials Comparing Fibrate Therapy With Placebo
Source
No.
Treatment, Active/Control
Follow-
up, y
Trial Population (Triglyceride
Inclusion Criteria) Age, y
Triglycerides
Fibrate Control
Baseline,
Mean (SD),
mg/dL
Difference
at 1 y, %
Coronary Drug Project,37,38
1975b
1103 2789 Clofibrate/placebo 6.2 Male, previous MI (NR) 184 25
WHO-COOP,39 1978b,d 5331 5296 Clofibrate/placebo 5.3 Male, upper third of cholesterol range
(NR)
46 NA NA
HHS,40,44 1987c 2362 2347 Gemfibrozil/placebo 5.0 Male, no CHD or possible symptoms
of CHD (NR)
47 177 (119) 35
VA-HIT,41 1999b 1264 1267 Gemfibrozil/placebo 5.1a Male, CHD (triglycerides300
mg/dL)
64 161 (68) 31
BIP,42 2000 1548 1542 Bezafibrate/placebo 6.2 Previous MI or stable angina
(triglycerides300 mg/dL)
60 145 (51) 21e
FIELD,12 2005 4895 4900 Fenofibrate/placebo 5.0a Diabetes mellitus, not taking statin
(triglycerides 89-445 mg/dL)
62 174 (78) 30
ACCORD Lipid,43 2010 2765 2753 Simvastatin fenofibrate/
simvastatin placebo
4.7 Diabetes mellitus, CVD or risk factors
(triglycerides750 mg/dL with
no lipid-lowering therapy;400
mg/dL with therapy)
62 162 (113-229)a 20
Total 19268 20894 5.3 (0.5)
Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; BIP, Bezafibrate Infarction Prevention; CHD, coronary heart disease; CVD, cardiovascular disease; FIELD, Feno-
fibrate Intervention and Event Lowering in Diabetes; HHS, Helsinki Heart Study; MI, myocardial infarction; NA, not available; NR, not reported (no triglycerides inclusion or exclusion criteria
specified); VA-HIT, Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Cholesterol Intervention Trial; WHO-COOP, World Health Organization Co-operative Trial.
SI conversion factor: To convert triglyceride values to mmol/L, multiply by 0.0113.
aMedian or median (interquartile range).
bOnly fatal cases of pancreatitis available.
c Includes cases from both the HHS and its ancillary study (age, baseline triglyceride levels, and % difference in triglyceride levels are weighted means).
d Includes cases during the trial and during first year after the trial.
eAverage difference during trial.
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of1175(95%CI,693-9195)over5years.
Therewaslimitedheterogeneitybetween
trials for incident pancreatitis (2=9.11;
I2=0%).
In5dose-comparisonstatintrialswith
39 614 participants conducted over 4.8
(SD,1.7)years,156participants(0.39%)
developedpancreatitis(70assignedtoin-
tensive dose, 86 assigned to moderate
dose) (RR, 0.82 [95% CI, 0.59-1.12;
P=.21]) (Table 1, Figure 2). There was
againlimitedheterogeneitybetweenthese
trials for incident pancreatitis (2=1.29;
I2=0%).
There was no evidence of statistical
heterogeneity between the analyses of
placebo-controlled trials and intensive-
dose/moderate-dose trials (P=.79 for
interaction).
In the combined data set of 21 trials,
465participants(0.30%)developedpan-
creatitis (of whom 204 were assigned to
statin therapy or intensive-dose statin
therapyand261wereassignedtoplacebo,
standard care, or moderate-dose statin
therapy,respectively)(RR,0.79[95%CI,
0.65-0.95; P=.01; 2=10.48; I2=0%])
(Table1,Figure2).Thisrepresentsanum-
berneededtotreatof1187(95%CI,731-
4768)over5years.Therewasnoevidence
of publication bias (P=.83) (eFigure 1A,
available at http://jama.com). Meta-
regression analysis found no relation-
ship across the trials between risk of pan-
creatitis and reduction in triglyceride
levels at 1 year, although this analysis was
of limited value given the limited statis-
tical heterogeneity between trial-
specific RRs (P=.23) (eFigure 2A).
Using a fixed-effects model ap-
proach produced results (RR, 0.79 [95%
CI 0.65-0.95; P=.01]) identical to those
of the random-effects model. In a sen-
sitivity analysis of only the 2 trials with
published data,22,36 122 participants
(0.37%) developed pancreatitis (52/
16 300 assigned to statin therapy or in-
tensive-dose therapy, 70/16 300 as-
signed to placebo or moderate-dose
statin therapy) (RR, 0.74 [95% CI, 0.52-
1.07; P=.11; 2=0.30; I2=0%]).
Fibrate Therapy and Pancreatitis
Sevenrandomizedclinical trialsof fibrate
therapy(4withpublisheddataand3with
unpublisheddataregardingincidentpan-
creatitis)provideddataon40 162partici-
pantsoveraweightedmeanfollow-uppe-
riodof5.3(SD,0.5)years.Baselineaverage
triglyceride levels inthetrialsvariedfrom
145 mg/dL to 184 mg/dL. Trials were of
high quality, with a median Jadad score
of5(range,5-5)and100%agreementbe-
tween reviewers. During this time, 144
participants (0.36%) developed pancre-
atitis (84 assigned to fibrate therapy, 60
assigned to placebo) (RR, 1.39 [95% CI,
1.00-1.95;P=.053])(Table2,FIGURE3).
Thisrepresentsanumberneededtoharm
Figure 2. Meta-analysis of Incident Pancreatitis in 21 Large Statin Trials
Control
Favors Statin Favors Control
0.01 101.0 1000.1
Risk Ratio (95% CI)
Cases Total
Statin
Cases TotalSource
Placebo- and standard care–controlled
Risk Ratio
(95% CI)Weight, %
7 22215 22234S,16 1994 0.71 (0.23-2.25)2.60
5 32932 3302WOSCOPS,17 1995 0.40 (0.08-2.06)1.28
17 207815 2081CARE,18 1996 0.88 (0.44-1.77)7.07
10 33017 3304AFCAPS/TexCAPS,19 1998 0.70 (0.27-1.84)3.67
23 450212 4512LIPID,20 1998 0.52 (0.26-1.05)7.02
2 21330 2138GISSI Prevenzione,21 2000 0.20 (0.01-4.16)0.37
41 10 26733 10 269HPS,22 2002 0.80 (0.51-1.27)16.29
11 29135 2891PROSPER,23 2002 0.46 (0.16-1.32)3.07
0 8000 800GREACE,24 2002 1.00 (0.02-50.46)0.22
16 51378 5168ASCOT-LLA,25 2003 0.50 (0.21-1.16)4.76
4 14105 1428CARDS,26 2004 1.23 (0.33-4.61)1.98
5 11993 1211ASPEN,27 2006 0.59 (0.14-2.49)1.67
3 39663 3866MEGA,28 2006 1.03 (0.21-5.09)1.34
7 249712 2514CORONA,29 2007 1.70 (0.67-4.33)3.94
17 890117 8901JUPITER,30 2008 1.00 (0.51-1.96)7.58
7 22897 2285GISSI-HF,31 2008 1.00 (0.35-2.86)3.12
Subtotal: I2 = 0.0%, P = .87 0.77 (0.62-0.97)65.98
Control
Favors Statin Favors Control
0.01 101.0 1000.1
Risk Ratio (95% CI)
Cases Total
Statin
Cases TotalSource
Intensive vs moderate dose
Risk Ratio
(95% CI)Weight, %
1 20631 2099PROVE-IT TIMI 22,32 2004 0.98 (0.06-15.72)0.45
2 22343 2265A to Z,33 2004 1.48 (0.25-8.86)
40 500633 4995TNT,34 2005 0.83 (0.52-1.31)16.05
14 444914 4439IDEAL,35 2005 1.00 (0.48-2.10)6.24
29 603319 6031SEARCH,36 2010 0.66 (0.37-1.17)10.22
Subtotal: I2 = 0.0%, P = .86 0.82 (0.59-1.12)34.02
Overall: I2 = 0.0%, P = .96 0.79 (0.65-0.95)100.00
For abbreviations, see Table 1. Size of data markers indicates relative weight of the study (from random-effects analysis).
LIPID-MODIFYING THERAPIES AND RISK OF PANCREATITIS
808 JAMA, August 22/29, 2012—Vol 308, No. 8 ©2012 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/ by a AUSTRALIAN CATHOLIC UNIVERSITY User  on 08/10/2017
of 935 (95% CI, 388 to50 000) over
5years.Therewas limitedheterogeneity
between trials for incident pancreatitis
(2=4.48; I2=0%). Likewise, there was
no evidence of publication bias (P=.59)
(eFigure 1B). Meta-regression analysis
found no relationship across the trials
between risk of pancreatitis and reduc-
tion in triglyceride levels at 1 year across
the trials (P= .81) (eFigure 2B), al-
though this analysis was of limited value
given the limited statistical heteroge-
neity between trial-specific RRs and the
similar relative reductions in triglycer-
ide levels achieved across the trials.
Using a fixed-effects model approach
produced results identical to those
achievedusingtherandom-effectsmodel
(RR,1.39[95%CI,1.00-1.95;P=.053]).
Inasensitivityanalysisofonly the4trials
withpublisheddata,12,37,39,4169participants
(0.26%)developedpancreatitis(44/12593
assignedto fibrate therapy,25/14 252as-
signed to placebo) (RR, 1.75 [95% CI,
1.07-2.86; P=.03; 2=1.19; I2=0%]).
COMMENT
This report of pooled randomized trial
data demonstrates that use of statin
therapy was associated with a reduc-
tion in the number of patients devel-
oping pancreatitis. Broadly similar re-
sults were obtained for statin compared
with placebo as well as for intensive-
dose statin therapy compared with
moderate-dose therapy, in keeping with
a dose-dependent association. How-
ever, we did not demonstrate an asso-
ciation between use of fibrate therapy
and risk of pancreatitis.
Previously published case reports and
observational pharmacoepidemiologic
studies have demonstrated an associa-
tion between statin therapy and in-
creased risk of pancreatitis.1-4 However,
such analyses are susceptible to bias by
unmeasured confounders and to con-
founding by indication. The present
analysis, however, indicates that statin
therapy may be associated with a re-
duced risk of pancreatitis overall. Al-
though we cannot completely exclude
the possibility that statin therapy may
lead toveryoccasional idiosyncratic cases
of pancreatitis, the randomized trial data
appear reassuring. Unlike fibrates, stat-
ins are not known to increase the risk of
developing gallstones.48 Studies show-
ing both a reduction in bile cholesterol
levels and an association with reduced
risk of gallstones with statin therapy sug-
gest the possibility of a protective ef-
fect.6,49 Furthermore, studies con-
ducted in animal models suggest that
statin therapy may be beneficial in both
establishedacutepancreatitis andchronic
pancreatitis.50-52
Major guidelines of lipid-modifying
therapysuchas theNationalCholesterol
Education Program Third Report of the
Expert Panel on Detection, Evaluation,
andTreatmentofHighBloodCholesterol
in Adults (NCEP ATP III)8 and the Na-
tionalInstituteforHealthandClinicalEx-
cellence (NICE) Type 2 Diabetes guide-
line9suggesttheadditionoffibratetherapy
in patients with moderately elevated tri-
glyceride levels andabove(400mg/dL
and500 mg/dL, respectively). This is
based on the rationale that hypertriglyc-
eridemiaisawell-recognizedcauseofpan-
creatitis andthat loweringof triglyceride
levels should be clinically beneficial.7
However, no convincing trial data exist
to support use of any agents for preven-
tionofpancreatitisinthisclinicalsituation.
ParticipantsintheCoronaryDrugProject
assignedtoclofibratewereat50%higher
risk of developing cholelithiasis or cho-
lecystitis than those receiving placebo,13
andgallstonesareawell-recognizedcause
of pancreatitis. In addition, it has been
demonstratedinsmallclinicalstudiesthat
both fenofibrate—a fibrate thought less
likelytocausegallstones—andbezafibrate
increase the cholesterol content of bile,
thereby theoretically increasing the risk
ofdevelopinggallstones.14,53Followingthe
CoronaryDrugProject,otherlargefibrate
trialsdidnot findasignificant increase in
the incidence of gallbladder disease, al-
though the total number of cases was
small.40,41,43 Ouranalysisdidnotdemon-
strate an association between fibrate
therapyandriskofpancreatitis,although
the analysis may have lacked statistical
powertoshowanincreasedriskinpatients
with slightly elevated triglyceride levels
(the range at baseline in the trials we ex-
amined was 145-184 mg/dL). It remains
possible,however,thatfibratesmighthave
adifferentneteffectinpatientswithhigher
triglyceride levels.
Although the present results for both
statinsand fibrates shouldbeconsidered
hypothesis-generatingandthenumberof
pancreatitis cases was small in this trial
populationat lowriskofpancreatitis, the
analysis raises questions regarding the
choice of lipid-modifying agents in pa-
Figure 3. Meta-analysis of Incident Pancreatitis in 7 Large Fibrate Trials
Control
Favors Fibrate Favors Control
0.01 101.0 1000.1
Risk Ratio (95% CI)
Cases Total
Fibrate
Cases TotalSource
Risk Ratio
(95% CI)Weight, %
1 27890 1103CORONARY Drug Project,37 1975 1.11
0 52963 5331WHO-COOP,39 1978 1.29
6 23473 2362HHS,40 1987 5.89
1 12671 1264VA-HIT,41 1999 1.47
6 15426 1548BIP,42 2000 8.82
23 490040 4895FIELD,12 2005 42.83
23 275331 2765ACCORD Lipid,43 2010 38.59
Overall: I2 = 0.0%, P = .61
0.84 (0.03-20.71)
6.95 (0.36-134.66)
0.50 (0.12-1.99)
1.00 (0.06-16.04)
1.00 (0.32-3.10)
1.74 (1.04-2.91)
1.34 (0.78-2.31)
1.39 (1.00-1.95)100.00
For abbreviations, see Table 2. Size of data markers indicates relative weight of the study (from random-effects analysis).
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tientswithhypertriglyceridemia.Inthose
with slightly elevated triglyceride levels,
statins appear better supported by the
availabledatathanfibrates forpreventing
pancreatitis.Lifestylemodificationsalso
remain important to improve lipid pro-
files in such individuals. Inpatientswith
severehypertriglyceridemia, a trial com-
paring fibratesandstatins forpreventing
pancreatitiswouldbeclinicallyvaluable.
Strengths of this meta-analysis are
that the analysis was conducted using
data from randomized trials, which
avoids most of the potential bias of un-
measured confounders encountered in
observational studies, and that we were
able to include data from almost all of
the relevant trials, both published and
unpublished, thereby maximizing
power and providing the best answer
possible with existing data.
Thismeta-analysisalsohasseverallimi-
tations. First, pancreatitis was not a pre-
specified end point in the trials, which
were primarily designed to assess the ef-
fectof lipid-modifyingtherapyoncardio-
vascular events.However, limitedstatis-
tical heterogeneity between trial results
for statins and fibrates, plus evidence of
adose-dependentassociation for statins,
providesconfidence in the findings. Sec-
ond, the occurrence of pancreatitis was
not recorded inastandardizedway,with
resultantvariationbetweentrials.There-
fore these results, especially for fibrate
therapy when there were relatively few
events dominated by 2 trials,12,43 should
be interpreted with caution.
Third,because itwas feltunlikely that
thecauseofpancreatitiswouldhavebeen
consistently recorded inanaccurateway
across trials, we were unable to examine
specific causes such as gallstones. Like-
wise, we were unable to separate reports
of pancreatitis into acute and chronic
cases. However, given that the majority
of trials used the presence of hepatobili-
ary disease as an exclusion criterion, it is
highly likely that themajorityofcases in-
cluded in this report represent de novo
acute pancreatitis. This is supported by
evidence from SHARP.5 Fourth, we did
nothaveaccess to individual-participant
data, which may have reduced our abil-
ity to identify any relationship with the
extentof triglyceride lowering.Fifth,be-
cause the trials tendedtoexcludepartici-
pantswithmarkedhypertriglyceridemia,
thesefindingsmaynotnecessarilybegen-
eralizabletothatspecificgroupofpatients.
In summary, pooled analyses of ran-
domized trial data suggest that statin
therapy is associated with a reduction in
theriskofpancreatitisinpatientswithnor-
malormildlyelevatedtriglyceride levels.
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